Associations of Estrogen Receptor Alpha Gene Polymorphisms with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 50 (06) ◽  
pp. 469-477 ◽  
Author(s):  
Jiajia Yang ◽  
Renfang Han ◽  
Mengya Chen ◽  
Yaping Yuan ◽  
Xingxing Hu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Estrogen Receptor ◽  
Estrogen Receptor Alpha ◽  
Meta Analysis ◽  
Pvuii Polymorphism ◽  
Xbai Polymorphism

AbstractThe associations between PvuII (T>C) and XbaI (A>G) polymorphisms of estrogen receptor alpha (ESR1) gene with type 2 diabetes mellitus (T2DM) or metabolic syndrome (MetS) are reported in many studies, but the results are inconsistent. This present work aims to assess the associations by performing a comprehensive meta-analysis. Relevant studies were searched through several databases. The pooled odd ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the associations of PvuII and XbaI polymorphisms with the risk of T2DM and MetS by using the STATA 14.0 software. Eight studies for T2DM and three articles about MetS were included in this meta-analysis. The overall results indicated that PvuII, rather than XbaI polymorphism, was associated with T2DM (regressive model: OR=0.673, 95% CI=0.550 to 0.823, praw<0.001, pFDR<0.003). The subgroup analysis based on race revealed an association of PvuII polymorphism with the decreased T2DM risk in Chinese population and a relationship between XbaI polymorphism and the reduced T2DM susceptibility in Caucasians. The difference of country may be one source of the heterogeneity for PvuII polymorphism and T2DM. However, neither PvuII nor XbaI polymorphism was related to the risk of MetS. The C allele of PvuII polymorphism presents a protective role in T2DM risk, especially in Chinese people. The G allele of XbaI polymorphism is related to a reduced risk for T2DM in Caucasian population. Nevertheless, neither of PvuII nor XbaI polymorphism is associated with MetS risk.

scholarly journals Quercetin promotes long noncoding RNA lncSHGL expression via estrogen receptor α to suppress type 2 diabetes mellitus in mice

2020 ◽  
Author(s):  
Hanlu Fan ◽  
Haiwen Li ◽  
Huijiao Liu ◽  
Peng Li ◽  
Xiaomeng Jia ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Estrogen Receptor ◽  
Noncoding Rna ◽  
Estrogen Receptor Alpha ◽  
Grape Pomace ◽  
Active Compounds ◽  
Organ Systems

Abstract Background Type 2 diabetes mellitus (T2DM) is the most common type of metabolic disorder involving multiple organ systems. Grape has been reported to improve the symptoms of T2DM, the precise mechanism of its action is unclear. Our study was aimed to determine the effect and mechanism of grape pomace extract in T2DM mice induced by high fat diet (HFD). Materials and methods Ultra-performance liquid chromatography and quadrupole time-of-flight mass spectrometry were used to identify the main active compounds in grape pomace extract to improve T2DM. C57BLK/6J mice induced by HFD supplemented with or without quercetin were used to show the effects of quercetin improving T2DM. By online database research, bioinformatics analysis and molecular biology experiments, Estrogen receptor alpha (ERα)-lncSHGL (lncRNA suppressor of hepatic gluconeogenesis and lipogenesis) pathway was identify as the target for quercetin. Results Quercetin was identified as one of the most active compounds in grape pomace extract to improve T2DM. Quercetin could inhibit HFD-induced T2DM in mice by activing ERα. LncSHGL was identified as the downstream of ERα and inhibited HFD-induced T2DM. Conclusions Quercetin could be beneficial for T2DM by promoting lncSHGL transcription and activating the lncSHGL pathway, and may be used as a drug component to treat T2DM.

scholarly journals Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Shu-ying Li ◽  
Ya-ling Zhao ◽  
Yu-fan Yang ◽  
Xi Wang ◽  
Min Nie ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Insulin Sensitivity ◽  
Meta Analysis ◽  
Metabolic Effects ◽  
Testosterone Replacement Therapy

Background. Testosterone replacement therapy (TRT) is commonly used for the treatment of hypogonadism in men, which is often associated with type 2 diabetes mellitus (T2DM) and metabolic syndrome (Mets). Recent compiling evidence shows that TRT has beneficial metabolic effects on these patients. Objective. A meta-analysis has been conducted to evaluate the effects of TRT on cardiovascular metabolic factors. Methods. We conducted a systemic search on PubMed, Embase, Cochrane Library, Wanfang, and CNKI and selected randomized controlled trials (RCTs) to include. The efficacy of TRT on glycemia, insulin sensitivity, lipid profile, and body weight was meta-analyzed by Review Manager. Results. A total of 18 RCTs, containing 1415 patients (767 in TRT and 648 in control), were enrolled for the meta-analysis. The results showed that TRT could reduce HbA1c (MD = −0.67, 95% CI −1.35, −0.19, and P = 0.006 ) and improve HOMA-IR (homeostatic model assessment of insulin resistance) (SMD = −1.94, 95% CI −2.65, −1.23, and P < 0.0001 ). TRT could also decrease low-density lipoprotein (SMD = −0.50, 95% CI −0.82, −0.90, and P = 0.002 ) and triglycerides (MD = −0.64, 95% CI −0.91, −0.36, and P < 0.0001 ). In addition, TRT could reduce body weight by 3.91 kg (MD = −3.91, 95% CI −4.14, −3.69, and P < 0.00001 ) and waist circumference by 2.8 cm (MD −2.80, 95% CI −4.38, −1.21 and P = 0.0005 ). Erectile dysfunction (measured by IIEF-5) did not improve, while aging-related symptoms (measured by AMS scores) significantly improved. Conclusions. TRT improves glycemic control, insulin sensitivity, and lipid parameters in hypogonadism patients with T2DM and MetS, partially through reducing central obesity.

scholarly journals Estrogen Receptor Alpha (Esr) Gene Polymorphism As Risk Factor For Type 2 Diabetes Mellitus (T2dm) In Javenese Menopause Women of Indonesia

2013 ◽  
Vol 12 (2) ◽  
pp. 172-179
Author(s):  
Syaefudin Ali Akhmad ◽  
Maliyah Madiyan ◽  
Pramudji Hastuti ◽  
Hemi Sinorita
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Estrogen Receptor ◽  
Risk Factor ◽  
Allele Frequency ◽  
Estrogen Receptor Alpha ◽  
Receptor Alpha ◽  
Menopausal Women

Background: The number of menopausal women who suffer from low level estrogen-associated type-2 diabetes has been increasing recently. The role of estrogen in metabolism of glucose depends on estrogen receptor alpha expression that is regulated by estrogen receptor alpha gene (ESR ?). PvuII and XbaI polymorphisms in the ESR ? receptor may decrease the expression of ESR ? protein and receptor activity, thereby increasing the risk of developing type 2 diabetes mellitus in menopausal women. Purpose: to determine the ESR ? polymorphism as a risk factor for type 2 diabetes mellitus (DM) in menopause women of Javanese in Indonesia. Methods: Sixty five menopausal women were recruited for the study consisted of 40 women with T2DM and 25 women as control. PvuII and XbaI polymorphisms were determined by polymerase chain reacton-restriction fragment length polymorphism (PCR-RFLP). The absence of PvuII and XbaI restriction sites were indicated by “P1” and “X1” and presence by “P2” and “X2”, respectively. Chai Square test were used in statistical analyisis to measure Hardy Weinberg Equilibrium (HWE) and the risk of P1/P2 and X1/X2 allele for suffering T2DM. Results: PvuII genotype was distributed as; 22.5% (P1P1), 45% (P1P2), 32.5% (P2P2) while XbaI genotype was distributed as 10 % (X1X1), 62.5% (X1X2) and 27.5% (X2X2) in diabetics respectively. There was no difference in distribution of P1 and P2 between diabetics and non diabetics but difference for X1 and X2 existed between groups. The frequency of P2 allele was 55 % while P1 allele frequency is 45% in diabetics. X2 allele frequency was 58.8% while X1 allele is 41.2%. X2 allele had an impact on the 3.6 times higher risk of getting type 2 diabetes in Javanese menopausal women (OR = 3.662, CI = 1.711 to 7.840). Conclusions: PvuII and XbaI polymorphism was found in Javanese menopause women of Indonesia in patients with type 2 diabetes mellitus. The allele frequency of P2 and X2 are 55% and 58.8% respectively. X2 allele was found as a risk factor for type 2 diabetes mellitus in Javanese menopause women of Indonesia. Bangladesh Journal of Medical Science Vol. 12 No. 02 April’13 Page 171-179 DOI: http://dx.doi.org/10.3329/bjms.v12i2.14946

Systematic Literature Review and Network Meta-analysis (NMA) of SGLT2i as Monotherapy for Type 2 Diabetes Mellitus (T2DM)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1159-P
Author(s):  
GLENN M. DAVIES ◽  
ANN MARIE MCNEILL ◽  
ELIZA KRUGER ◽  
STACEY L. KOWAL ◽  
FLAVIA EJZYKOWICZ ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document